TABLE 1.
Clinical characteristics of included patients.
| Variables | Total (n = 750) |
| Demographics information | |
| Age, years (IQR) | 62 (53–69) |
| Male, n (%) | 543 (72.4) |
| Vascular risk factors | |
| Cigarette smoking, n (%) | 388 (51.7) |
| Alcohol consumption, n (%) | 314 (41.9) |
| Hypertension, n (%) | 384 (51.2) |
| Diabetes mellitus, n (%) | 139 (18.5) |
| Coronary heart disease, n (%) | 146 (19.5) |
| Atrial fibrillation, n (%) | 74 (9.9) |
| Previous stroke, n (%) | 103 (13.7) |
| Dyslipidemia, n (%) | 313 (41.7) |
| History of previous medications | |
| Antihypertensive therapy, n (%) | 300 (40) |
| Hypoglycemic therapy, n (%) | 121 (16.1) |
| Antiplatelet therapy, n (%) | 98 (13.1) |
| Baseline SBP, mmHg (IQR) | 154 (139–167) |
| Baseline DBP, mmHg (IQR) | 89 (81–98) |
| Baseline blood glucose, mmol/L (IQR) | 7.6 (6.5–9.2) |
| Baseline NIHSS score (IQR) | 8 (5–12) |
| ONT, min (IQR) | 184 (141–229) |
| TOAST | |
| Large-artery atherosclerosis, n (%) | 274 (36.5) |
| Small-vessel occlusion, n (%) | 280 (37.3) |
| Cardioembolism, n (%) | 84 (11.2) |
| Other determined etiology, n (%) | 12 (1.6) |
| Undetermined etiology, n (%) | 100 (13.3) |
| Laboratory tests | |
| ALP, U/L (IQR) | 75.7 (62.2–92) |
| Globulin, g/L (IQR) | 27.1 (24.3–29.8) |
| Clinical outcomes | |
| HT, n (%) | 117 (15.6) |
| Poor outcome, n (%) | 452 (60.3) |
IQR, inter quartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; ONT, onset to needle time; TOAST, Trial of Org 10172 in acute stroke treatment; ALP, alkaline phosphatase; HT, hemorrhagic transformation.